Tyrphostin AG 825 has been used to study its effects on iodide uptake in EMT6 cells1.
Biochem/physiol Actions
EGF receptor tyrosine kinase inhibitor, inactive against IGF-1 Receptor.
Tyrphostin AG 825 has been used in combination with hypericin-mediated photodynamic therapy (HY-PDT) for evaluating its therapeutic effects in HER2 overexpressing human breast cancer cells. This study reported that AG 825 combination increased the induction of cell death, HER2 degradation and inhibited colony formation in cancer cells2.
Features and Benefits
This compound is a featured product for Kinase Phosphatase Biology research. Click here to discover more featured Kinase Phosphatase Biology products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
Preparation Note
Tyrphostin AG 825 is soluble in DMSO and methanol.
Photochemistry and photobiology, 86(1), 200-205 (2009-11-17)
Current treatment of breast cancer is often affected by resistance to therapeutics, for which the human epidermal growth factor receptor 2 (HER2) may be responsible. Here, we report for the first time the use of hypericin-mediated photodynamic therapy (HY-PDT) in
International journal of cancer, 125(12), 2783-2791 (2009-07-02)
The sodium iodide symporter (NIS) mediates iodide uptake into the thyroid. Because of this mechanism, differentiated thyroid cancer is susceptible for radioiodine therapy. Functional NIS expression in extrathyroidal tumors has been reported mainly in breast cancer. We screened colorectal tumors
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.